Jump to content

Methamphetamine: Difference between revisions

From Pharmacopedia
[checked revision][pending revision]
Pharmacopedia: add <pharmaInteractions/>
Assign pharmacological categories from List_of_CNS-active_medicines
Line 62: Line 62:
}}
}}


[[Category:Stimulants & Wake-Promoting Agents]]
[[Category:Amphetamines]]
[[Category:Psychostimulants]]
[[Category:Psychostimulants]]

Revision as of 15:06, 14 May 2026

Psychostimulant, Amphetamine
Methamphetamine
Desoxyn
Methamphetamine is a CNS stimulant of the amphetamine class. It is FDA-approved (as Desoxyn) for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

<indication slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/> <indication slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

  • Attention and focus👤 no reports yet⚕️ no reports yet
  • Wakefulness👤 no reports yet⚕️ no reports yet
  • Motivation and drive👤 no reports yet⚕️ no reports yet
  • Mild euphoria👤 no reports yet⚕️ no reports yet
  • Decreased appetite/Anorexia👤 no reports yet⚕️ no reports yet
  • Dry mouth👤 no reports yet⚕️ no reports yet
  • Elevated heart rate / blood pressure👤 no reports yet⚕️ no reports yet
  • Insomnia👤 no reports yet⚕️ no reports yet
  • Irritability👤 no reports yet⚕️ no reports yet
  • Anxiety👤 no reports yet⚕️ no reports yet
  • Headache👤 no reports yet⚕️ no reports yet
  • Weight loss👤 no reports yet⚕️ no reports yet
  • Palpitations👤 no reports yet⚕️ no reports yet
  • Jaw clenching / bruxism👤 no reports yet⚕️ no reports yet
  • Stereotyped behaviors👤 no reports yet⚕️ no reports yet
  • Agitation👤 no reports yet⚕️ no reports yet
  • Psychosis👤 no reports yet⚕️ no reports yet
  • Mania👤 no reports yet⚕️ no reports yet
  • Dependence / misuse👤 no reports yet⚕️ no reports yet
  • Tolerance👤 no reports yet⚕️ no reports yet
  • Serious cardiac event👤 no reports yet⚕️ no reports yet
  • Seizure/Epileptic fit👤 no reports yet⚕️ no reports yet
  • Hyperthermia👤 no reports yet⚕️ no reports yet
  • Serotonin syndrome👤 no reports yet⚕️ no reports yet
  • Withdrawal/Discontinuation Syndrome👤 no reports yet⚕️ no reports yet

+ Add an effect

Pharmacokinetics

Metabolism

Hepatic metabolism includes N-demethylation to amphetamine (an active metabolite).

Elimination

Urinary elimination is pH-dependent.

Pharmacodynamics

Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.

Interactions

  • MAOIs — contraindicated (per label)
  • Acidifying agents — increase urinary clearance
  • Alkalinizing agents — decrease urinary clearance
No interactions reported yet.

Pregnancy and lactation

Category C per Desoxyn label.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

Mixed amphetamine salts, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Dexmethylphenidate, Modafinil

References

Pharmacy
Starting dose
5 mg PO
Preparations
Desoxyn 5 mg tabs
US FDA Max
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
Common uses
Structure
Structure of Methamphetamine
Classification(s)
Classes
Psychostimulant, Amphetamine
Pharmacology
Routes
Oral (prescribed)
Pregnancy
Category C (per Desoxyn label)
Legal status
Schedule II
Purported mechanism
Monoamine releasing agent — TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport